Abstract
Any biopharmaceutical product that has involved the use of animal-derived material during the manufacturing process has the potential to be contaminated with animal viruses. To ensure safety of these products, extensive testing is performed on the starting materials, such as the cell banks, and on the raw materials used in manufacture. Additional testing is also performed at various stages of production and, in some cases, on the final product as well. Because of inherent limitations in direct testing methods, the capacity of the downstream purification process to remove/inactivate potential viral contaminants is also studied to give an extra degree of assurance that the final product will be free of infectious viruses.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Biologicals Control Act of 1902 (1902).
Fox, J. P., Lennette, E. H., Manso, C., and Aquiar, J. R. (1942) Observation on the occurrence of icterus in Brazil following vaccination against yellow fever. Am. J. Hyg. 36, 68–116.
Harris, R. J. C., Dougherty, R. M., Biggs, P. M., Payne, L. N., Goffe, A. P., Churchill, A. E. (1966) Contaminant viruses in two live virus vaccines produced in chick cells. J. Hyg. (Cambridge) 64, 1–6.
Murray, R. (1967) Contemporary problems in regulating the potency and safety of viral vaccines, in First International Conference on Vaccines against Viral and Rickettsial Diseases of Man. Scient. Publ. No. 147, Washington D.C., Pan American Health Organization, WHO, pp. 577–580.
Brown, P., Gajdusek, D. C., Gibbs, C. J., Jr, and Asher, D. H. (1985) Potential epidemic of Creutzfeld-Jacob disease from human growth hormone therapy. N. Engl. J. Med. 313, 728–731.
Ben-Hur, E. and Horowitz, B. (1996) Virus Inactivation in blood. AIDS 10, 1183–1190.
RL Garnick, R. L. (1996) Experience with viral contamination in cell culture, in Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products, Dev. Biol. Stand., Basel Karger, Vol 88, pp. 49–56.
Willkommen, H. (1996) Presentation at BioEast Meeting, January, Washington DC.
Kappeler, A., Lutz-Wallace, C., Sapp, T., and Sidhu, M. (1996) Detection of bovine polyomavirus contamination in fetal bovine sera and modified live viral vaccines using polymerase chain reaction. Biologicals 24(2), 131–135.
Harasawa, R. and Tomiyama, T. (1994) Evidence of pestivirus RNA in human virus vaccines. J. Clin. Microbiol. 32(6), 1604,1605.
Harasawa, R. and Mizusawa, H. (1995) Demonstration and genotyping of pestivirus RNA from mammalian cell lines. Microbiol. Immunol. 39(12), 979–985.
O’Toole, D., Van Campen, H., and Woodard, L. (1994) Bluetongue virus: contamination of vaccine. J. Am. Vet. Med. Assoc. 1;205(3), 407,408.
Levings, R. I., Wilbur, L. A., Evermann, J. F., et al. (1996) Abortion and death in pregnant bitches associated with a canine vaccine contaminated with blue-tongue virus, in Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products, Dev. Biol. Stand., Basel Karger, Vol 88, pp. 219–220.
Rabenau, H., Ohlinger, V., Anderson, J., et al. (1993) Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV). Biologicals 21(3), 207–214.
Senda, M., Parrish, C. R., Harasawa, R., et al. (1995) Detection by PCR of wild-type canine parvovirus which contaminates dog vaccines. J. Clin. Microbiol. 33(1), 110–113.
Linnen, J., Wages, J., Zhang-Keck, Z. Y., et al. (1996) Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 27, 505–508.
Moore, S. J., Gao, G., Dominguez, E., et al. (1996) Primary characterization of a herpesvirus agent associated with Kaposi’s sarcoma. J. Virol. 70, 549–558.
CPMP Ad Hoc Working Party on Biotechnology/Pharmacy. (1991) Note for Guidance: Validation of Virus Removal and Inactivation Procedures III/8115/89.
Office of Biologics Research and Review, Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (Food and Drug Administration, Bethesda, MD, 1987).
Federal Health Office and Paul Ehrlich Institute Federal Office for Sera and Vaccines (1994) Notice on the Registration of Drugs: Requirements for Validation Studies to Demonstrate the Virus Safety of Drugs Derived from Human Blood or Plasma. Bundesanzeiger 84, 4742–4744.
Federal Health Office and Paul Ehrlich Institute Federal Office for Sera and Vaccines Announcement on Measures for Averting Risks from Medicinal Products. (1994) Reducing the Risk of Transmitting Haematogenous Viruses with Medicinal Products made by Fractionation from Plasma of Human Origin.
The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit-CPMP Biotechnology Working Party Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses, (CPMP/BWP/268/95 Final Version 2, Canary Wharf, London, 1996).
The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit — CPMP Biotechnology Working Party Medicinal Products Derived from Human Plasma, (CPMP/BWP/268/95 Final Version 2, Canary Wharf, London, 1996).
Office of Biologics Research and Review, Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (Food and Drug Administration, Bethesda, MD, 1993).
Office of Biologics Research and Review, Draft Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (Food and Drug Administration, Bethesda, MD, 1994).
Center for Biologics Evaluation and Research, Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (Food and Drug Administration, Rockville, MD, 1997).
ICH Topic Q5A. Step 4 Consensus Guideline, Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin, CPMP/ICH/295/95. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Canary Wharf, London (1997).
Sofer, G. (1996) Validation: Ensuring the accuracy of scaled-down chromatography models. Biopharm. 9(9), 51–54.
Darling, A. J., Kreuzberg-Duffy, U., Borland, L., Morrow, A., Berglof, J. H., and Andersson, I. (1994) Validation of chromatographic procedures used in the fractionation of plasma derivatives, in Animal Cell Technology: Products of Today, Prospects for Tomorrow. Spier, R. E., Griffith, J. B., and Berthold, W., eds. Butterworth-Heinemann Ltd., Oxford, pp. 567–570.
Hyclone Laboratories Inc., (1992) Freezing and Thawing Serum and Other Biological Materials. Art to Science 11(2), 1–7.
ICH Guideline on “Validation of Analytical Procedures: Definitions and Terminology; Availability,” Federal Register 4, 11,259–11,262, (1 March 1995).
Darling, A. J. and Spaltro, J. J. (1996) Process Validation for Virus Removal. Considerations for Design of Process Studies and Viral Assays. BioPharm 9(9), 42–50.
Spearman, C. and Kaerber, G. (1974) In: Bibrack, B. and Wittmann, G., eds. Virologische Arbeitsmethoden. Stuttgart: Fischer Verlag, 37–39.
Little, L. E. (1995) Validation of Immunological and Biological Assays. Biopharm Nov. 36–42.
United States vs Barr Laboratories, Inc.; Civil Action No. 92–1744, U.S. District Court for the District of New Jersey; 812F. Supp. 458; 1993 U.S. Dist. Lexis 1932; 4 February 1993, as amended 30 March 1993.
Prusiner, S. B. (1995) The prion diseases. Sci. Am. 272(1), 48–51, 54–7.
Westaway, D., Carlson, G. A., and Prusiner, S. B. (1995) On safari with PrP: prion diseases of animals. Trends Microbiol. 3(4), 141–147.
Note for Guidance on Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products — CPMP/CVMP EMEA/410/01 — February 2001.
Notification of the Safety Requirements for Pharmaceuticals Made From Body Components of Cattle, Sheep or Goats for the Protection Against the Risk of Transmission of BSE and Scrapie — BGA, Germany Feb. 1994.
Notification Concerning the Approval and Registration of Pharmaceuticals of 28 March 1996 Protection Against Pharmaceutical Product Risks, Level II — BfArM, Federal Institute for Pharmaceuticals and Medicinal Products, Germany.
Will, R. G., Ironside, J. W., Zeilder, M., et al. (1996) A New Variant of Creutzfeldt-Jakob Disease in the UK, Lancet 374, 921–925.
Lasmezas, C. I., Deslys, J.-P., Demaimay, R., et al. (1996) BSE Transmission to Macaques. Nature 381, 743,744.
Telling, C., Scott, M., Hsiao, K. K., et al. (1994) Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein, Proc. Natl. Acad. Sci. USA 91, 9936–9940.
Houston, F., Foster, J. D., Chong, A., Hunter, N., Bostock, C. J. (2000) Transmission of BSE by blood transfusion in sheep. Lancet 356, 999–1000.
Lee, D. C., Stenland, C. J., Hartwell, R. C., et al. (2000) Monitoring plasma processing steps with a sensitive Western Blot assay for the detection of prion protein, J. Virol. Methods 84, 77–89.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Darling, A. Validation of biopharmaceutical purification processes for virus clearance evaluation. Mol Biotechnol 21, 57–83 (2002). https://doi.org/10.1385/MB:21:1:057
Issue Date:
DOI: https://doi.org/10.1385/MB:21:1:057